Mitchell A Lazar
Dr. Mitchell Lazar is the Willard and Rhoda Ware Professor of Diabetes and Metabolic Diseases and Director of the Institute for Diabetes, Obesity, and Metabolism at the University of Pennsylvania. He received an S.B. degree in Chemistry from M.I.T., and a PhD in Neurosciences as well as an MD from Stanford University. He trained in Internal Medicine at Brigham and Women’s Hospital and in Endocrinology at MGH before joining the Penn faculty. Dr. Lazar discovered the circadian nuclear receptor REV-ERBa, as well as its heme ligand, transcriptional repression function, and interactions with corepressors and HDAC3. His work has demonstrated the fundamental importance of REV-ERBa in the physiology of circadian rhythms and metabolism. Dr. Lazar also discovered that PPARg is predominantly expressed in adipocytes, and has been a leader in understanding of PPARg function at a genome-wide level. He discovered resistin as a novel adipocyte hormone that impairs insulin action and first member of a new family of secreted molecules. Dr. Lazar has served on numerous editorial and scientific advisory boards and councils, and has received major awards from the NIH, the American Thyroid Association, the American Society for Clinical Investigation, and the Endocrine Society, as well as the Rolf Luft Award of the Karolinska Institute. He is also an elected member of the National Academy of Medicine, the American Academy of Arts and Sciences, and the National Academy of Sciences of the USA
Abstracts this author is presenting: